CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.
CARGO Therapeutics Stock Down 2.5 %
NASDAQ:CRGX traded down $0.11 during midday trading on Tuesday, hitting $4.13. The company had a trading volume of 47,524 shares, compared to its average volume of 514,109. The stock's fifty day moving average price is $4.19 and its 200-day moving average price is $10.36. The company has a market capitalization of $190.20 million, a PE ratio of -0.97 and a beta of 0.47. CARGO Therapeutics has a 52-week low of $3.00 and a 52-week high of $25.45.
Analyst Upgrades and Downgrades
CRGX has been the topic of a number of recent research reports. Piper Sandler downgraded shares of CARGO Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $34.00 to $4.00 in a research report on Thursday, January 30th. JPMorgan Chase & Co. cut CARGO Therapeutics from an "overweight" rating to an "underweight" rating in a research report on Thursday, January 30th. Jefferies Financial Group downgraded shares of CARGO Therapeutics from a "buy" rating to a "hold" rating and decreased their price objective for the company from $32.00 to $3.00 in a research report on Thursday, January 30th. Chardan Capital cut shares of CARGO Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, January 30th. Finally, HC Wainwright downgraded CARGO Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $15.00.
Get Our Latest Stock Report on CRGX
About CARGO Therapeutics
(
Get Free Report)
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CARGO Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.
While CARGO Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
